Based in Vero Beach, Florida, Quinton Oswald is an executive with a diverse background in the biotech industry. He formerly served as the CEO of Notal Vision in Manassas, Virginia. During his tenure, Quinton Oswald played a key role in expanding a patient-based diagnostic and monitoring platform for the early identification of the switch from dry to wet age-related macular degeneration (AMD).

He also previously lead the launch of the first effective treatment for Wet AMD,Lucentis while heading a Business Unit at Genentech.This was after his role as Senior VP of Novartis Ophthalmology for North America which commecialized Visudyne.

Wet AMD, also called advanced neovascular AMD, wet AMD is an eye disease that causes rapid loss of central vision. Wet AMD happens when abnormal blood vessels grow in the macula, a tissue in the back of the eye that plays a critical role in channeling central vision light signals to the brain for processing. One effective treatment for vision loss from wet AMD is Lucentis (the brand name of the drug ranibizumab).

Lucentis is a prescription medication that hinders the growth of abnormal blood vessels in the macula. The drug suppresses the manifestation of wet AMD and slows vision loss. Lucentis works by blocking a chemical called VEGF that is crucial for abnormal blood vessel formation in the eye.

Doctors inject Lucentis into the eye. Common side effects include eye pain, blurry vision, eye redness, and sensitivity to light. These effects are temporary.